HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)

• Status: Completed
• Trial end date: 2017-06-30
• Target enrollment: 0
• Participant gender: All

Summary

STRIDE2 is a longitudinal, non-randomized study of individuals living with HIV who are dependent on opioids. This study is funded by the National Institute on Drug Abuse (R01DA030768, Altice, PI; Taxman & Lawson, Co-PIs) and is being conducted by George Mason University, Yale University, and Howard University.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Collaborators: George Mason University; Howard University; National Institute on Drug Abuse (NIDA)
• Treatments: Buprenorphine

Criteria

Inclusion Criteria:

1. HIV+, confirmed by rapid HIV test

2. Meet DSM-IV criteria for opioid dependence

3. 18 years or older

4. Have health insurance that is accepted at Lab Corp.

Exclusion Criteria:

1. Are <18 years old;

2. Are HIV negative;

3. Are Unable to communicate in English;

4. Are not able to provide informed consent;

5. Do not meet DSM-IV criteria for opioid dependence;

6. Plan to leave the DC area